Embecta (EMBC) Projected to Post Earnings on Friday

Embecta (NASDAQ:EMBC) is anticipated to release its earnings data before the market opens on Friday, February 14th. Analysts expect Embecta to post earnings of $0.45 per share for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Trading Down 2.6 %

EMBC stock opened at $17.73 on Friday. The firm has a 50 day moving average of $19.70 and a 200-day moving average of $16.52. Embecta has a 12 month low of $9.93 and a 12 month high of $21.48. The firm has a market capitalization of $1.03 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 0.97 and a beta of 1.20.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were given a dividend of $0.15 per share. The ex-dividend date was Friday, December 6th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.38%. Embecta’s dividend payout ratio (DPR) is presently 44.44%.

Analyst Upgrades and Downgrades

EMBC has been the subject of a number of research analyst reports. BTIG Research upgraded Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Wednesday, November 27th. Morgan Stanley raised Embecta from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $13.00 to $20.00 in a research note on Monday, December 2nd.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.